Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to $110.3 million.

  • Beam Therapeutics' Current Deferred Revenue rose 2350.13% to $110.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.3 million, marking a year-over-year increase of 2350.13%. This contributed to the annual value of $108.9 million for FY2024, which is 3904.72% down from last year.
  • As of Q3 2025, Beam Therapeutics' Current Deferred Revenue stood at $110.3 million, which was up 2350.13% from $105.8 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Current Deferred Revenue ranged from a high of $348.6 million in Q4 2021 and a low of $10.0 million during Q2 2021
  • For the 5-year period, Beam Therapeutics' Current Deferred Revenue averaged around $133.0 million, with its median value being $112.7 million (2022).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 145228750.0% in 2021, then tumbled by 4947.98% in 2024.
  • Beam Therapeutics' Current Deferred Revenue (Quarter) stood at $348.6 million in 2021, then fell by 2.99% to $338.2 million in 2022, then crashed by 47.19% to $178.6 million in 2023, then plummeted by 39.05% to $108.9 million in 2024, then rose by 1.34% to $110.3 million in 2025.
  • Its Current Deferred Revenue stands at $110.3 million for Q3 2025, versus $105.8 million for Q2 2025 and $85.2 million for Q1 2025.